Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032357 · ClinicalTrials.gov registry record · Phase 3
Does the Reduction of Total Body Iron Storage (TBIS) Alter Mortality in a Population of Patients With Advanced PVD?
A Phase 3 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,277
- Enrollment target
NCT00032357: Completed Phase 3 study, sponsored by US Department of Veterans Affairs.
NCT00032357 is a Phase 3 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 1,277 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00032357, a Phase 3 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,277 participants
- Enrollment target
Study Summary
Veterans Affairs Cooperative Study #410, The Iron and Atherosclerosis Trial, FeAST, a 24-hospital prospective randomized single-blinded clinical trial of graded iron reduction was conducted between May 1, 1999 and April 30, 2005, and has now been completed. A total of 1,277 primarily male participants with peripheral arterial disease were entered. The primary outcome was all cause mortality and the secondary outcome combined death plus non-fatal myocardial infarction (MI) and stroke.
Primary Outcome
The primary objective of this study is to evaluate the effectiveness of a reduction of Total Body Iron Stores (TBIS) in decreasing the rate of all cause mortality in patients with peripheral vascular disease (PVD).
Interventions
- PROCEDURE Ferritin reduction to 25 ng/ml by phlebotomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,277 participants |
| Start Date | 1999-05 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
What the finished NCT00032357 record still lists
NCT00032357 is an interventional study that assigns participants to a tested intervention. Its 1,277 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% higher).
The record links to 0 conditions, and to 1 intervention - of which Ferritin reduction to 25 ng/ml by phlebotomy is the first listed.
NCT00032357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00032357 about?
NCT00032357 is a clinical study titled "Does the Reduction of Total Body Iron Storage (TBIS) Alter Mortality in a Population of Patients With Advanced PVD?". Veterans Affairs Cooperative Study #410, The Iron and Atherosclerosis Trial, FeAST, a 24-hospital prospective randomized single-blinded clinical trial of graded iron reduction was conducted between May 1, 1999 and April 30, 2005, and has now been completed. A total of 1,277 primarily male participan...
What is the current status of trial NCT00032357?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,277 participants. The study started on 1999-05. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00032357?
The interventions under investigation include: Ferritin reduction to 25 ng/ml by phlebotomy (PROCEDURE).
Who is sponsoring clinical trial NCT00032357?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00032357's enrollment target sits among peer trials
1,277 200th of 2000 higher than 1,801 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07001800 · 1,276 participants · Phase 2
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
- NCT07225504 · 1,275 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia